NEXT LEVEL MULTIDISCIPLINARY
CANCER CARE

Cancer is complicated, and so is cancer treatment. The Institute of Medicine recommends a patient-centered, team-based model of care for cancer patients. This is where multidisciplinary cancer (MDC) care comes in. The team approach brings together experts from across disciplines to discuss a patient case, define a care path, and share the latest research and treatments available. But the operationalization of an MDC care approach is challenging. Barriers to data sharing, provider communication and collaboration, and patient visibility have limited the adoption of an MDC approach despite its proven positive impact on patient lives. OncoLens is the first comprehensive cancer care platform designed around multidisciplinary care. The solution amplifies complex decisions and care planning so that the value of the MDC approach reaches from diagnosis through to survivorship.

According to the American Society of Clinical Oncologists (ASCO), a Tumor Board is “a group of doctors and other health care providers with different specialties that meets regularly at the hospital to discuss cancer cases and share knowledge.” Sometimes referred to as a cancer conference, Tumor Boards serve as a structured opportunity for multiple clinicians, including pathologists, surgeons, clinical oncologists, and radiologists, to discuss a patient case. In addition to supporting multidisciplinary care goals, Tumor Boards also educate providers, serve as an opportunity to share best practices, and identify new treatment options including clinical trials.

A Molecular Tumor Board (MTB) is a type of tumor board that includes discussion and review of a patient’s genomic and genetic profile. It is typically part of a precision medicine approach that combines genomic data and clinical attributes to create a personalized treatment plan. Many times, a patient referred to an MTB has a complex type of cancer or a cancer that was unresponsive to standard treatment. Understanding and actioning genetic alterations is complex and challenging. Therapies, guidelines, available clinical trials, and our understanding of how alterations contribute to cancer and responsiveness to drugs constantly changes. OncoLens helps reduce this complexity by facilitating MTBs and incorporating the latest thinking in precision medicine including benchmarks from COSMIC and other databases directly into the staging and biomarker discussion.

Informatics helps oncologists use big data to match patients to the appropriate treatments or clinical trials, or to identify gaps in care. OncoLens is a leading provider in Oncology informatics for multidisciplinary teams.

OncoLens works with various Cancer Registry software like OncoLog and CRStar to deliver integrations via easy export and import of NAACCR reports, saving your cancer registry teams valuable time in case finding.

MDT stands for multidisciplinary team. MDTs help coordinate cancer care and organize experts from across disciplines to assess, plan, and manage a patient’s cancer care journey.

OncoLens supports Tumor Boards by integrating data from multiple sources across the care continuum. The solution reduces the labor-intensive, manual processes that drive provider burnout and limit the number of patients discussed within the Tumor Board setting. OncoLens ensures that participating clinicians, regardless of their facility or network, have the documentation they need, converting unstructured data to structured, usable data and providing the ability to communicate and collaborate with their peers. As a result, providers who leverage OncoLens have realized an up to 44 percent increase in the number of cases reviewed at Tumor Boards and increased clinical trial accrual across disease sites.

OncoLens goes beyond the Tumor Board to bring the expertise and insights documented and actioned as part of the Tumor Board through to every aspect of cancer care, including survivorship. Data is streamlined and updated as new insights are uncovered. Protocols and best practices are shared across providers, the network, and the broader oncology community. Providers have realized up to a 90% increase in multidisciplinary cancer care team efficiency and coordination. And OncoLens eliminates the artificial data and location barriers that limit engagement, lower referrals, and impact patient care. While OncoLens brings virtualization natively into the multidisciplinary cancer care workflow, that is just one part of our solution functionality. It is something that a provider can choose to use if it makes sense for the program. OncoLens isn’t about virtualization—we are about true multidisciplinary cancer care that leads to better health, greater knowledge sharing, and decision making.

Some EMRs are building tumor board meeting facilitation capabilities into their solutions. While these forms may help to organize and capture data, they cannot enable or facilitate multidisciplinary decision making. EMRs do not provide a longitudinal view of the cancer patient and the patient journey; and EMRs are not tied to cancer quality, leading cancer practices, and accreditation standards. EMRs are fundamentally billing systems. OncoLens integrates with EMRs to capture and make use of patient information collected within the EMR and transforms this data into inputs that support multidisciplinary cancer care, tracking of quality, adherence to care pathways.

OncoLens helps match patients to your local and affiliated clinical trials’ inclusion and exclusion criteria giving your research team a significantly narrowed down list of patients matching to your trials. This pre-screen enables your team to focus on the most relevant patients. OncoLens also embeds automated clinical trial matching for any patient presented for multi-disciplinary discussion, ensuring that providers have visibly into the options that are a fit for a specific patient.

OncoLens simplifies the CME process by tracking attendance, auto-creating CME flyers, and producing the attendance reports required by your accrediting organizations. Reporting is multi-level so that you can see your CME progress and status at the organizational, event, and provider levels.

OncoLens continuously monitors accreditation standards including the Commission on Cancer (CoC), National Accreditation Program for Breast Centers (NAPBC) and National Accreditation Program for Rectal Cancer (NAPRC). The platform incorporates the quality metrics necessary in each relevant case discussion. Reports customized to the specific needs of the accrediting bodies can then be downloaded at any point of time, eliminating the workload needed to track, collate, and build reports manually. Reach out to find how OncoLens informatics solutions support other accreditation programs.

OncoLens has established scripts and data formats for the major ONC Certified EMRs, including EPIC, Cerner, OncoEMR, athenahealth, Mosaiq, ARIA and more. We eliminate many of the challenges created by EMRs and enhance the EMR experience by consolidating data, eliminating dual entry, finding and extracting critical information through natural language processing, and creating a longitudinal view of the patient that can be shared across clinical team members on multiple EMRs across multiple networks.

OncoLens delivers seamless integration into the cancer registry software to accelerate the identification and intake of new cancer cases for abstracting. Data collected by OncoLens can be imported directly at any time—immediately after each Tumor Board or Cancer Conference, at set intervals, in batches based on tumor type—based on your workflow.

OncoLens is fully HIPAA compliant, SOC2 certified and includes advanced security options such as single sign on (SSO) to drive better security, ease of use, and flexibility.

OncoLens partners with clinical trial sponsors and clinical research organizations (CROs) to find trials that maybe a match for your patient base. In addition, OncoLens’ patient id is specifically tuned to help you identify patient matches and send you alerts. Our reports are based on daily updates through connectivity to your EHR.

OncoLens mines unstructured and structured data including pdfs through Natural Language Processing (NLP) and OCR (Optical Character Recognition) to extract key insights including biomarkers, staging or particular keywords such as drugs or symptoms. Through specialized connections between those keywords, OncoLens can then identify if the patient might have a rare condition for which there might have even been a mis-diagnosis or coding.